Low-Dose IL-2 Therapy for Core Autism Symptoms Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autism spectrum disorder (ASD) are inadequate in addressing core symptoms, and there are no effective preventive options available for ASD.
Innovation Solution
The use of interleukin-2 (IL-2), particularly in low doses, to treat and prevent ASD by administering it to pregnant mothers at risk or to children diagnosed with or at risk of ASD, optionally conjugated with PEG or Fc fragment to enhance its half-life and diffusion in the central nervous system.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If psychopharmacological options are used for treating unspecific symptoms of ASD, then irritability and hyperactivity are reduced, but core symptoms of ASD are not reliably improved
Solution Approach 1:
The patent extracts and treats the underlying immune system dysfunction (maternal immune activation) separately from the behavioral symptoms. By targeting the root cause (immune dysregulation) rather than just the symptoms, the treatment addresses core ASD symptoms that psychopharmacology cannot reliably improve.
Solution Approach 2:
The patent applies preliminary action by intervening during pregnancy (before ASD symptoms manifest) to prevent the development of core symptoms. Maternal IL-2 treatment during pregnancy prevents the immune-mediated disruption of fetal neurodevelopment, thereby preventing core ASD symptoms before they occur.
2Reliability
If no preventive options are available for ASD, then occurrence and development of ASD cannot be prevented, but with IL-2 treatment during pregnancy, prevention becomes possible
Solution Approach 1:
The patent implements preliminary action by administering IL-2 to pregnant mothers to prevent ASD before it occurs. This proactive approach during the critical period of fetal neurodevelopment allows prevention of core symptoms, transforming ASD from an untreatable condition into a preventable one.
Solution Approach 2:
The patent applies preliminary anti-action by using IL-2 to counteract maternal immune activation before it can cause damage to fetal neurons. The treatment prevents the harmful immune response from disrupting neurodevelopment, thereby preventing ASD occurrence.
3Reliability
If IL-2 is administered to improve half-life and diffusion in CNS, then treatment efficacy is enhanced, but molecular complexity increases
Solution Approach 1:
The patent uses composite materials by conjugating IL-2 with PEG (polyethylene glycol) or Fc fragments. This creates a composite molecule that combines IL-2's therapeutic activity with PEG's ability to extend half-life and Fc's capacity to enhance diffusion across the blood-brain barrier, thereby improving treatment efficacy.
Solution Approach 2:
The patent introduces PEG and Fc fragments as intermediaries that facilitate IL-2's delivery to the CNS. These intermediary molecules act as carriers that enhance IL-2's pharmacokinetic properties and enable its diffusion across the blood-brain barrier to reach target sites in the central nervous system.
Data Source
AI summary
The invention relates to the use of IL-2 in treating autism spectrum disorder (ASD) in a subject, as well as in preventing ASD in children, by administering the IL-2 to a child at risk of ASD or to a pregnant mother at risk of having a child with ASD.